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Vaxtracker  is  a  web  based  survey  for  active  post  marketing  surveillance  of  Adverse  Events  Following
Immunisation.  It is designed  to efﬁciently  monitor  vaccine  safety  of  new  vaccines  by  early  signal  detec-
tion  of  serious  adverse  events.  The  Vaxtracker  system  automates  contact  with  the  parents  or  carers  of
immunised  children  by email  and/or  sms message  to  their  smart  phone.  A hyperlink  on the  email  and
text messages  links  to a web  based  survey  exploring  adverse  events  following  the immunisation.  The
Vaxtracker  concept  was  developed  during  2011  (n = 21),  and  piloted  during  the 2012  (n  = 200)  and  2013
(n  =  477)  inﬂuenza  seasons  for children  receiving  inactivated  inﬂuenza  vaccine  (IIV)  in the  Hunter  Newdverse Events Following Immunisation
AEFI)
ost marketing surveillance
ctive surveillance
nline survey
nﬂuenza vaccine
England  Local  Health  District,  New  South  Wales,  Australia.  Survey  results  were  reviewed  by  surveillance
staff  to detect  any  safety  signals  and compare  adverse  event  frequencies  among  the  different  inﬂuenza
vaccines  administered.  In  2012,  57%  (n = 113)  of the  200  participants  responded  to the  online  survey  and
61%  (290/477)  in  2013.  Vaxtracker  appears  to  be  an  effective  method  for  actively  monitoring  adverse
events  following  inﬂuenza  vaccination  in  children.
ht  © 2Crown  Copyrig
. Introduction
Inactivated inﬂuenza vaccines (IIV) are prepared annually with
imited safety and efﬁcacy trials able to be performed before a
ew inﬂuenza strain is included in the formulation [1]. Active post
arketing surveillance of IIV has not routinely been conducted in
ustralia. Local side effects, such as swelling, redness and pain at
he injection site, are common, occurring in more than 10% of recip-
ents. Fever, tiredness and myalgia also occur commonly (1–10%).
n children less than ﬁve years of age, these adverse events may  be
ore pronounced [2].
In Australia in 2010 the inactivated CSL IIV caused an excessf febrile reactions including febrile convulsions (up to 1 per 100)
3]. A joint working group of the Therapeutic Goods Adminis-
ration (TGA) and the Australian Technical Advisory Group on
∗ Corresponding author. Tel.: +61 2 49246477; fax: +61 2 49246490.
E-mail addresses: Patrick.Cashman@hnehealth.nsw.gov.au (P. Cashman),
arah.moberley@gmail.com (S. Moberley), Craig.Dalton@hnehealth.nsw.gov.au
C. Dalton), Jody.Stephenson@hnehealth.nsw.gov.au (J. Stephenson),
lissa.Elvidge@hnehealth.nsw.gov.au (E. Elvidge),
ichelle.Butler@hnehealth.nsw.gov.au (M.  Butler),
avid.Durrheim@hnehealth.nsw.gov.au, David.Durrheim@newcastle.edu.au
D.N. Durrheim).
ttp://dx.doi.org/10.1016/j.vaccine.2014.07.061
264-410X/Crown Copyright © 2014 Published by Elsevier Ltd. This is an open acce
y-nc-sa/3.0/).014  Published  by  Elsevier  Ltd. This  is  an  open  access  article  under  the CC
BY-NC-SA  license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Immunisation (ATAGI) investigated data on the safety of differ-
ent brands of 2010 and 2011 IIVs in children and adults. In its
December 2011 report the working group recommended that:
“options for enhanced surveillance, designed to detect clinically
important differences in the safety proﬁle of inﬂuenza vaccines, be
explored to reinforce public and provider conﬁdence in program
safety” [4]. A separate independent investigation recommended
that Adverse Events Following Immunisation (AEFI) reporting by
consumers themselves be incorporated into the notiﬁcation system
[5]. A subsequent review undertaken by former Australian Chief
Medical Ofﬁcer, Professor John Horvarth AO, recommended more
timely AEFI reporting and electronic collection of vaccine usage and
safety data [6].
A novel active online surveillance system (Vaxtracker) was tri-
alled for Adverse Events Following Immunisation during the 2012
and 2013 inﬂuenza seasons. Vaxtracker is based on the success of
the ‘Flutracking’ inﬂuenza-like-illness surveillance platform, which
has been used in Australia nationally since 2006 and success-
fully engages over 15,000 community members in regular weekly
reporting during each inﬂuenza season [7]. In 2011, 21 children
were enrolled using email surveys alone to reﬁne the surveillance
concept. In 2012, 200 children were enrolled from 16 general med-
ical practices in Newcastle and the Children’s Hospital Westmead,
Sydney. This testing resulted in: a new platform that was  more
ss article under the CC BY-NC-SA license (http://creativecommons.org/licenses/
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obile phone browser compatible to enhance readability and inter-
ction on a mobile phone and an automated email to Vaxtracker
eam members alerting them that a serious symptom had been
eported (hospitalisation and seizure). We  report on the evaluation
f the systems performance in the 2013 inﬂuenza seasons.
. Methods
In 2013, 15 large general medical practices in the Newcastle
etropolitan and Tamworth rural population centres in northern
SW participated (Fig. 1). The general practice clinics were vis-
ted by a Vaxtracker staff member to demonstrate the system and
nswer questions. Prior to inﬂuenza vaccination, participating clin-
cs provided parents and carers with an information sheet (Fig. 2)
n the Vaxtracker programme and they were asked if they would
ike to participate. Following parental consent, clinic staff enrolled
articipants by entering the child’s name and their parent or carer’s
ontact details (email, mobile phone number or both) and brand of
IV administered into a simple secure web-based form.
The Vaxtracker system automated contact with the parents or
arers of immunised children by email and/or sms  message to their
mart phone after the child has received an inﬂuenza immunisa-
ion. Each participant was automatically contacted to complete
wo online surveys, the ﬁrst to explore for initial reactions and a
nal survey to capture any late reactions. The ﬁrst survey reminder
as sent three days after the immunisation to facilitate timely sig-
al detection and the ﬁnal survey 42 day post-vaccination, which
as considered adequate to detect rare late adverse events such as
uillain–Barré syndrome. Participants who did not respond to the
rst survey did not progress to be sent the ﬁnal survey on day 42.
Children who  receive IIV for the ﬁrst time are recommended to
ave two doses of IIV at a one month interval [2]. These children
eceived an automated reminder when the second IIV dose was  due
one month later) and a link to the Vaxtracker survey was sent three
ays after the second dose due date. Participants received a link to
 Vaxtracker online survey after both dose one and dose two  of IIV.
The online survey sent on day 3 after the ﬁrst and second IIV
oses was structured to collect information on 11 symptoms, while
he day 42 survey for late adverse events only enquired about visits
o hospital. Delayed participant survey responses were accepted
ntil the end of the inﬂuenza season.
The online survey took less than a minute for parents and car-
rs to complete if there were no symptoms to report and a few
inutes if symptoms were reported. To decrease data entry for the
linic staff date of birth and gender were entered on-line by survey
espondents. The survey provided simple check-boxes and free text
oxes as required.
The 2013 Vaxtracker online survey was simpliﬁed by adding
 screening question so that the 11 symptom questions only
ppeared if the parent or carer clicked “yes” to the question: “Did
child’s ﬁrst name) experience and kind of reaction, illness or dis-
omfort after the vaccination?” An answer of “yes” to any of the
ymptom questions in the ﬁrst online survey activated a drop down
ox with additional questions regarding severity, whether medi-
al advice was sought and duration of the event. The 11 symptoms
xplored in the 2012 and 2013 pilot studies were: reaction at injec-
ion site, fatigue, inﬂuenza-like illness, muscle aches, headaches,
oint pain, fever, lymph node swelling, weakness, seizures and
other” symptoms.
Recruitment and adverse events were reviewed by surveillance
taff to detect any signal of adverse events. Data on recruitment and
dverse events were available through the dedicated secure web-
ite and was downloaded twice weekly to monitor adverse events,
ecruitment by each clinic and prepare weekly reports. An auto-
ated email alert to the Vaxtracker team was generated when a
eizure or hospitalisation was reported so that review could occur2 (2014) 5503–5508
rapidly. Survey completion rates were calculated as the number of
participants who  completed the survey divided by the total par-
ticipants due to have completed the survey. Weekly reports were
shared with health departments at State and National level and a
ﬁnal report with the Therapeutic Goods Administration (TGA).
All serious adverse events including high fever, seizures, unre-
solved systemic symptoms or hospitalisation were followed up by
telephone by a registered nurse and reviewed with a public health
physician and if required notiﬁed to NSW Health through usual AEFI
notiﬁcation channels. Adverse events were described according to
demographic characteristics of the participants, previous vaccine
history and the brand of IIV administered. Factors associated with
adverse events were investigated by comparing participants who
experienced an adverse event with those who did not experience
an adverse event by the following factors; age (t test of mean age),
gender and ﬁrst year of IIV administration (comparison of propor-
tions using Pearsons Chi-squared test). The analysis controlled for
gender, age by year and whether ﬁrst time inﬂuenza vaccine was
received in the current season. There is a Vaxtracker Standing Oper-
ating Procedure for validating reports that are questionable with
attending clinicians.
Surveillance of AEFIs is conducted in NSW under the NSW Pub-
lic Health Act, therefore ethical review was not required for this
enhancement to existing surveillance.
3. Results
Between 21 March and 30 June 2013, a total of 477 participants
who received IIV were recruited to Vaxtracker. Of these 290 (61%)
parents or carers completed the Vaxtracker online survey at day 3
following the ﬁrst dose of IIV with 134 (47%) of those went on to
complete the ﬁnal survey at day 43 (Fig. 3). Most respondents to the
online survey were aged between 5 years and 9 years 11 months
(55%), 32% were aged between 2 and 5 years and 12% aged less than
2 years. 53% of respondents were males (n = 154).
The mean number of days from sending the web survey link
to completion of the survey dispatched on day 3 was 3.33 days
(n = 290). The mean number of days from sending web survey link
to completion of the ﬁnal 42 day survey was  2.01 days (n = 120).
Survey completion rates were highest when both email and
mobile phone contact details were provided (n = 35, 74%) compared
to email (n = 135, 58%) or mobile phone (n = 120, 60%) alone. Among
the 477 participants, Vaxigrip (Sanoﬁ) (n = 334) was the most com-
monly administered IIV, followed by Fluarix (GlaxoSmithKline)
(n = 78), Inﬂuvac (Abbott) (n = 59), Vaxigrip Junior (Sanoﬁ) (n = 4)
and Agrippal (Novartis) (n = 2).
Eighteen percent of respondents in the day three survey
(52/290) reported any reaction following dose 1 across all IIV
brands, three of whom reported receipt of another vaccine within
one week of IIV administration. Over-all 8% of respondents (23/290)
experienced a local reaction and 3% (8/290) reported fever.
When considering speciﬁc IIV brands, Vaxtracker found a higher
rate of all reported reactions following Vaxigrip/Vaxigrip jnr (21.5%
(95% CI: 16.0–27.0%); n = 46/214) compared to all the other inactiv-
ated vaccine brands administered to participants (7.9% (95% CI:
1.8–14.0%); n = 6/76, p = 0.0079) (Table 1). However for fever there
was no signiﬁcant difference between Vaxigrip/Vaxigrip jnr (2.8%
(95% CI: 0.6–5.0%); n = 6/214) and the other brands of IIV (2.6% (95%
CI: 0.0–6.2%); n = 2/76, p = 0.9270).
Participants who  had received an IIV in the previous year also
appeared to have a higher rate of reactions than participants who
did not (25.8% versus13.2% respectively). The odds of having a reac-
tion for those who had IIV last year compared to those who  did not
is 1.95 (p = 0.036) when controlling for vaccine type, gender and
age.
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Fig. 1. Vaxtracker clinic locations 2013, Hunter New England Local Health District, NSW, Australia.
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Vaxtracker – monitoring children for adverse reactions to 
vaccines
Vaxtracker is an online  sur vey that checks  in w ith parents a fter their chi ldren are  vaccinated  
to monitor f or ad vers e reactions t o vacc inatio n.  
What h app ens when  you join?  
•  You  will complete this form  providing  your email address or  mobile phone number (i f 
you have a smart phone with internet access) and your child’s name.   
• The clinic will enter this information into a confidential online database plus the date 
of vaccination and the brand of influ enza  vac cine your child received . 
•  3 days  aft er the v acc ination, you  will receive an email or SMS link to an  online survey  
with quest ions  about  any react ions.   
• You will receive a final online survey 42 days after the first influenza vaccination.  
• The survey takes about 30 seconds to complete if your child has not had a reaction 
but could take several  minutes  if t here was  a reaction to report.  
• If your child has a reaction and you have agreed to a follow up phone call, a nurse 
may contact you to  ask for further in formation. 
How to  join 
Please complete this form and re turn it t o the clinic  administra tive staff.  
Yes, I would like Vaxtracker to  email me  and mo nitor my  child for adverse reactions to 
influenza immunisation . 
Child s name and  surname:   ________________________________________________ 
Parents email address & 
 or mobil e number  (smart phones only) :________________________________   
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Of the 134 respondents who completed the ﬁnal survey,
hree (2.2%) reported a hospitalisation in the 42 day period
ollowing vaccination which triggered an email alert and clini-
al review on all three occasions. However, on clinical review
ach hospitalisation episode was determined to be unrelated
o vaccination (two asthmatic children had experienced asthma
ttacks and one child had suffered a fracture following an
ccident).
able 1
dverse events following the ﬁrst dose of inactivated inﬂuenza vaccine by brand in 2013
Agrippal Fluarix In
All participants 2 78 5
Participants 1st survey 1 43 3
Any  adverse event 1st dose 0 5 (11%) 
Serious adverse event – 0 
Sought medical attention – 0 
Reaction at injection site – 1 
Fever  – 1 
Headaches – 2 
Fatigue – 1 
Joint  pain – 0 
Inﬂuenza-like illness – 2 
Lymph  node swelling – 1 
Seizures – 0 
Muscle aches – 2 
Weakness – 1 
Other symptoms – 1 nt information sheet.
4. Discussion
The Vaxtracker surveillance system found an intriguing differ-
ence in adverse event reaction rates between inﬂuenza vaccine
brands in this cohort of children. Most focus is on fever following
the febrile convulsion experience in Australia in 2010 and impor-
tantly Vaxtracker found no difference in rates of parent reported
fever across the brands of IIV.
 Vaxtracker survey participants. Participants could report multiple adverse events.
ﬂuvac Vaxigrip Vaxigrip Jnr Total
9 334 4 477
2 212 2 290
1 (3%) 46 (22%) 0 52 (18%)
0 0 – 0
0 4 – 4
1 21 – 23 (8%)
1 6 – 8 (3%)
0 7 – 9
0 14 – 15
0 6 – 6
1 9 – 12
0 2 – 3
0 0 – 0
0 12 – 14
0 1 – 2
0 8 – 9
P. Cashman et al. / Vaccine 3
Participants  rec ruite d 
from
15 clinics, n=5 17
Survey 1 (sent day 3 post vaccine) 
completed n=290/477  
61%
Excluded   
Aged >1 0 year s n =2 0 
Incorrect contact details n=20 
Final survey (sent da y 43  post 
vaccine) completed n=134/290 
47%
Excluded  
Did not complete  first  surve y n= 172 
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[6] Horvath J. Review of the management of adverse events associated with PanvaxFig. 3. Vaxtracker recruitment and retention, 2013.
Passive surveillance systems are able to identify safety sig-
als, but are subject to known limitations, due to underreporting,
elayed reporting and a lack of denominator data. Active surveil-
ance in a deﬁned cohort of vaccines can complement passive
urveillance by overcoming problems of delayed and underre-
orting and enabling calculation of adverse event rates. Recent
tudies internationally have emphasised the importance of active
urveillance to detect important signals early so that appropriate
nvestigations can be launched and necessary actions taken [8,9].
Internationally the usefulness of Patient Reported Outcomes
PROs) utilising available internet tools has been increasingly
ecognised. There is evidence that in relation to adverse events
ROs can identify real-world signals earlier and in higher volume,
ccurately characterise the signals, allow a focus on speciﬁc events
r populations of interest, and permit ongoing efﬁcient safety mon-
toring [10].
The ﬁnding that there was a signiﬁcantly higher rate of reactions
n participants who received IIV in the previous year deserves fur-
her investigation as it has not been a consistent ﬁnding in previous
tudies [3].
The initial practice visit by Vaxtracker staff of this pilot phase
ould be replaced by a brief diagrammatic user guide or online
eb demonstration to further improve efﬁciency and reduce the
ost of the roll out phase. We  estimate that once established the
ngoing human resources to operate the system are not great as
urvey results provide sufﬁcient information for assessment and
ery few respondents require subsequent telephone clariﬁcation
f clinical details or support. After the Vaxtracker survey was com-
leted by respondents, case review and data analysis for signal
etection quickly take place. The automatic management of sur-
ey dispatch and return of completed surveys and email alerts has
llowed for the efﬁcient and prompt review of AEFIs and rapid data
nalysis and rate calculation.
It is essential to reassure the community of vaccine safety and to
rompt early investigation should severe reactions occur or if there
s an unexpected increase in the frequency of clinical events [11].
he Vaxtracker active surveillance system achieved encouraging
ompletion rates. These were found to be higher where parents
eceived both mobile phone and email reminders.
Feedback and a certiﬁcate of appreciation were provided to
ll General Practice clinics that enrolled participants. Respondents
ho reported serious AEFI were contacted by telephone to dis-
uss their report, ensure that appropriate clinical management had
ccurred if required and enquire whether symptoms had resolved.2 (2014) 5503–5508 5507
There was  no formal feedback to respondents in this pilot but plans
are underway to make Vaxtracker safety data available to the pub-
lic on a website as the programme is expanded. Previous studies
have found differences in adverse event rates between inﬂuenza
vaccine brands in children [12]. Our ﬁndings support the need to
conﬁrm this differential rate in a larger cohort of children.
Vaxtracker has been adopted for active surveillance of IIV in
the community by the AusVaxSafety consortium and expanded
for use in two  Australian states, New South Wales and Victoria.
Sites selected include paediatric hospitals and general practice sett-
ings. To maintain the simplicity of Vaxtracker data for clinicians
the collection of additional data to provide a richer analysis, such
as medical conditions, will be collected from respondents when
completing the online survey.
5. Conclusions
The need to ensure high quality active surveillance for safety
signals when introducing new vaccines at population level has
been increasingly recognised. Early experience with the Vaxtracker
on-line surveillance system suggests that it provides effective post-
marketing surveillance, which is ideally suited to the introduction
of vaccines for children. It allowed rapid analysis of reported
adverse events by public health authorities.
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